Skip to content

Sepetaprost

Drug profile

Also known as: DE-126, ONO-9054, setaneo

PMDA approved

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Sepetaprost is a drug catalogued in DrugCentral. It was first approved by the PMDA in 2025. DrugCentral lists 2 molecular targets, including PTGFR and PTGER3. Recorded indications include Glaucoma.

  • Molecular targets: PTGFR and PTGER3 (2 listed in DrugCentral).
  • Indications: Glaucoma.
  • Molecular formula: C26H36F2O6; molecular weight 482.56 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Glaucoma

Mechanism & targets

Molecular targets (2)

TargetGeneActionActivity
Prostaglandin F2-alpha receptorPTGFRagonistEC50 7.65
Prostaglandin E2 receptor EP3 subtypePTGER3agonistEC50 7.54

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2025-08-25PMDA—Santen Pharmaceutical Co., Ltd.

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Sepetaprost is on its molecule page.

Molecular formulaC26H36F2O6
Molecular weight482.56 g/mol
CAS number—
InChIKeyBKVUSNOUTQMSBE-XCMGCKIWSA-N
PubChem CID50902259
CC(C)OC(=O)CCC[C@H]1CC[C@H]2[C@H](C[C@H]([C@@H]2/C=C/[C@H](COC3=C(C=CC(=C3)F)F)O)O)OC1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Sepetaprost used for?

DrugCentral lists the following indications for Sepetaprost: Glaucoma.

How does Sepetaprost work?

Its molecular targets in DrugCentral include PTGFR (agonist) and PTGER3 (agonist).

When was Sepetaprost first approved?

Sepetaprost was first approved by the PMDA in 2025.

What is the chemical formula of Sepetaprost?

Sepetaprost has the molecular formula C26H36F2O6 and a molecular weight of 482.56 g/mol.

Browse: all drugs starting with S · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval2025-08-25
AgencyPMDA
Targets2
Indications1
FormulaC26H36F2O6
DrugCentral ID5805
Interactive profile